In todays Fin Review a spec buy from Bell Potter, i think...

In todays Fin Review a spec buy from Bell Potter, i think conservative but might get a few on board reading article, here is excerpt.

"Neuren Pharmaceuticals , 16 per cent owned by property magnate Lang Walker , “has the best risk-reward of the biotech world we have looked at since we first started pushing Mesoblast at 50¢ in 2009," Bell Potter told clients in a research note on Friday.
Orphan drugs are for rare diseases with less than 200,000 patients in the US or 250,000 in Europe. Neuren plays in this space which is “very hot in terms of big pharma globally at the moment," Bell Potter said. “But given the lack of exposure to in Australia to this sector, “most analysts and clients don’t understand the opportunity."
Neuren is developing orphan drugs to treat Rett Syndrome and Fragile X.
In terms of the core markets, Bell Potter sees Fragile X as being a 70,000 patient market in the US “and, at say, $100,00 per annum per patient that would be a $7 billion value end market and there is no drug that treats the disease at the moment. Rett syndrome is a 16,000 patient market and at similar pricing would be a $1.6 billion revenue end market"

Read more: http://www.copyright link/business/...y-at-bell-potter-20131114-ijabe#ixzz3rE2sz1JH
Follow us: @FinancialReview on Twitter | financialreview on Facebook